Heart failure & cardiomyopathiesSecondary analysis
Finerenone in Women and Men With Heart Failure With Mildly Reduced or Preserved Ejection Fraction
- Secondary analysis of the FINEARTS-HF randomised trial
- prespecified analysis
- phase 3
- 653 sites in 37 countries
Authors' conclusion
In FINEARTS-HF, finerenone reduced the risk of the primary end point similarly in women and men with heart failure with mildly reduced or preserved ejection fraction. Finerenone had similar tolerability in women and men.
Study context
- Population
- Adults aged ≥40 years with symptomatic heart failure (HF) and left ventricular ejection fraction (LVEF) ≥40%, women and men2,732 women (45.5%)
- Participants
- 6,001 adults
- Comparison
- Finerenone vs placebo, by sex
- Primary endpoint
- CV death and total (first and recurrent) HF events (unplanned HF hospitalizations or urgent HF visits)
Primary result
As reported in the abstract
Primary outcome by sex
Finerenone vs PlaceboRate ratio (95% CI)
women
0.78(0.65–0.95)
men
0.88(0.74–1.04)
Further findings
Primary outcome incidence rate by sex (per 100 person-years)
Components of primary outcome and all-cause mortality
- Consistent effects by sex
Kansas City Cardiomyopathy Questionnaire-Total Symptom Scores (KCCQ-TSS) change · baseline to 12 months
- Greater improvement with finerenone regardless of sex
- interaction P = .73
Safety
Tolerability
- Similar tolerability in women and men
Original publication
Finerenone in Women and Men With Heart Failure With Mildly Reduced or Preserved Ejection Fraction. JAMA Cardiol. Published 1 January 2025. doi:10.1001/jamacardio.2024.4613
Summarised from the published abstract; every number is checked against it